Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Spanning nine influenza seasons, these studies enrolled 1862 patients, of whom 954 received the high-dose vaccine and 908 the standard-dose vaccine. Primary outcomes were immunogenicity (measured ...

The Subject Expert Committee (SEC) under the COVID-19 division of the Central Drugs Standard Control Organization (CDSCO) has ...

The H5N1 avian influenza virus has infected birds and mammals around the world. As of June 2025, 70 people have been infected ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.

Novavax's stand-alone trivalent flu and dual Covid-19-influenza vaccines had similar immune responses to those seen in other licensed brands, according to phase 3 trial data. The Gaithersburg, Md ...

The HSS has terminated a contract previously awarded to Moderna to help advance a vaccine candidate targeting bird flu.

Phase 1/2 H5 avian flu vaccine study shows positive interim results. Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines ...

Phase 1/2 H5 avian flu vaccine study shows positive interim results. Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines ...